Published in J Clin Endocrinol Metab on January 09, 2007
A HapMap harvest of insights into the genetics of common disease. J Clin Invest (2008) 18.31
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci (2010) 3.09
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP × environment regression coefficients. Genet Epidemiol (2011) 1.71
The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies. BMC Med Genet (2008) 1.68
Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care (2009) 1.29
Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol (2009) 1.19
The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia (2007) 1.08
Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. Med Princ Pract (2010) 1.01
Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study. Diabetologia (2009) 1.00
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care (2013) 0.98
Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals (Basel) (2010) 0.97
Susceptibility to type 2 diabetes mellitus--from genes to prevention. Nat Rev Endocrinol (2014) 0.94
Association of type 2 diabetes susceptibility loci with one-year weight loss in the look AHEAD clinical trial. Obesity (Silver Spring) (2012) 0.92
The complex interplay of genetic and lifestyle risk factors in type 2 diabetes: an overview. Scientifica (Cairo) (2012) 0.89
Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med (2011) 0.87
Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol (2013) 0.86
No interactions between previously associated 2-hour glucose gene variants and physical activity or BMI on 2-hour glucose levels. Diabetes (2012) 0.86
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics (2014) 0.85
PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease. PPAR Res (2008) 0.83
Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clin Immunol (2015) 0.83
Ordered stratification to reduce heterogeneity in linkage to diabetes-related quantitative traits. Obesity (Silver Spring) (2008) 0.82
PPARγ2 polymorphism and human health. PPAR Res (2009) 0.82
Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert Opin Pharmacother (2008) 0.82
Genetic susceptibility to type 2 diabetes and implications for therapy. J Diabetes Sci Technol (2009) 0.82
Clinical translation of genetic predictors for type 2 diabetes. Curr Opin Endocrinol Diabetes Obes (2009) 0.81
Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics (2008) 0.81
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. Pharmgenomics Pers Med (2009) 0.81
Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review. Genet Med (2013) 0.79
Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR Res (2008) 0.79
Diabetes prevention: can insulin secretagogues do the job? Prim Care Diabetes (2010) 0.77
Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? PPAR Res (2015) 0.77
Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. PLoS One (2015) 0.77
Effect of the PPARG2 Pro12Ala Polymorphism on Associations of Physical Activity and Sedentary Time with Markers of Insulin Sensitivity in Those with an Elevated Risk of Type 2 Diabetes. PLoS One (2015) 0.76
Inherited destiny? Genetics and gestational diabetes mellitus. Genome Med (2011) 0.76
Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders. J Dev Behav Pediatr (2016) 0.75
Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes. Int J Mol Sci (2016) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care (1999) 16.79
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet (2000) 15.19
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care (2000) 10.08
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet (1998) 8.02
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med (2006) 7.75
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 6.53
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet (2003) 3.67
Genetic prediction of future type 2 diabetes. PLoS Med (2005) 2.98
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 2.80
Testing for population subdivision and association in four case-control studies. Am J Hum Genet (2002) 2.26
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev (2004) 2.04
The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun (2000) 1.91
Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet (2005) 1.26
The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord (2000) 1.26
Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun (1999) 1.26
Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord (2000) 1.25
Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res (2004) 1.22
Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. Diabetologia (1994) 1.18
Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care (2003) 1.17
The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes (2001) 1.17
Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes (2002) 1.16
Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes (1999) 1.11
Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia (2004) 1.10
Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab (2000) 1.02
Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes (2005) 1.01
Examining the relationships between the Pro12Ala variant in PPARG and Type 2 diabetes-related traits in UK samples. Diabet Med (2005) 1.01
Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes. Diabetes Care (2003) 0.96
Is a Pro12Ala polymorphism of the PPARgamma2 gene related to obesity and type 2 diabetes mellitus in the Czech population? Ann N Y Acad Sci (2002) 0.89
The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study. J Clin Endocrinol Metab (2005) 0.87
The Pro12Ala polymorphism of PPARgamma2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract (2003) 0.87
Peroxisome proliferator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism (2000) 0.86
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
The structure of haplotype blocks in the human genome. Science (2002) 50.88
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet (2008) 19.55
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Replicating genotype-phenotype associations. Nature (2007) 16.11
Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet (2008) 15.89
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Calibrating a coalescent simulation of human genome sequence variation. Genome Res (2005) 15.04
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet (2006) 14.76
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med (2007) 12.24
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Methods for high-density admixture mapping of disease genes. Am J Hum Genet (2004) 12.02
Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol (2008) 11.28
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet (2008) 9.52
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
Demonstrating stratification in a European American population. Nat Genet (2005) 9.49
Testing for an unusual distribution of rare variants. PLoS Genet (2011) 9.28
Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature (2012) 8.91
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet (2007) 8.74
Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med (2010) 8.70
Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med (2008) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care (2007) 8.43
Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet (2009) 8.39
Comparison of fine-scale recombination rates in humans and chimpanzees. Science (2005) 7.86
Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 7.83
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med (2006) 7.75
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med (2012) 7.51
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet (2006) 7.49
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07
A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet (2006) 6.98
Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med (2010) 6.84
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet (2005) 6.61
Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U S A (2004) 6.53
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet (2008) 6.42
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Hypoglycemia in diabetes. Diabetes Care (2003) 6.19
The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12